Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at email@example.com if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
This comprehensive resource covers product change evaluation, postmarket surveillance, audit/inspection compliance, and various other laws and regulations pertaining to maintaining a product on the market.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Regulatory News | 07 March 2016 | By Zachary Brennan
Counterfeits of Gilead’s mega-blockbuster hepatitis C treatment Harvoni, which is generating billions per quarter in sales for the company, are emerging in Israel.
Switzerland’s drug regulator Swissmedic said over the weekend that the plastic bottles of the counterfeits, which originated in India, were imported via a Swiss trading company and “contain white instead of genuine yellow film-coated tablets,” the regulator said.
Swissmedic is working with other EU authorities to establish whether Harvoni packs with counterfeit contents have also been imported into other countries.
The counterfeit versions of the hepatitis C treatment, which have a list price in the US of $94,500 for a 12-week regimen, come as Swissmedic acknowledges that many Swiss patients are purchasing Harvoni abroad because of the price is dramatically lower in other countries like India and Egypt.
The discovery of counterfeit Harvoni comes as hepatitis C patients in the US and EU are increasingly coming up with unique ways to obtain Gilead’s drugs, which are sold for a fraction of the US list price in other countries. In October, Gilead reported Q3 sales of $4.8 billion for its two hepatitis C drugs.
Swissmedic advises against purchasing any medicine from unknown sources, and particularly against ordering them via the Internet.
“There is no guarantee that medicines sold at very low prices from countries with no comparable medicines control system actually contain the declared active ingredient or the correct dosage of that active ingredient,” Swissmedic said.
The Drug Regulatory Authority of Pakistan (DRAP) also has uncovered illegal manufacturing of Gilead’s other hepatitis C product Sovaldi (sofosbuvir).
Gilead in 2014 licensed 11 generic Indian drugmakers, including Hetero Labs, Cipla and Aurobindo Pharma, to make and sell generic versions of Sovaldi in almost 100 developing countries, and Mylan has already launched its generic version. The company has also said it would launch its own branded version of Sovaldi in India at a price of $300 per month.Swissmedic Announcement
Tags: Harvoni, Sovaldi, Gilead, Hepatitis C drug fakes, fake drugs online